Results from SC+ Human Factors Testing Published in Hemodialysis International

SC+ confirmed as safe and easy to use with minimal training

Alcester, Warwickshire, UK, 15 April 2019: Quanta Dialysis Technologies Ltd ("Quanta" or the "Company"), a pioneering British medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announces that results from its human factors testing (HFT) of SC+ have been published in Hemodialysis International, a leading peer-reviewed journal for the renal community.

SC+ was designed to empower patients to take control of their lives by making selfcare and home haemodialysis more accessible through a device that is small, simple to use, and powerful enough to deliver dialysis adequacy. This addresses the need for a dialysis system that is appealing to patients while also being suitable for use across the continuum of care, from the clinic to the home.

To evaluate whether SC+ could be used safely and effectively, and as part of the product design usability validation, HFT was performed with 17 healthcare professionals (nephrology nurses and healthcare assistants) and 15 home users (patients and caregivers). The HFT involved between 4.5 and 6 hours of training and, after a period of training decay of at least a day, a subsequent test session in which participants were assessed independently performing tasks on SC+. Between the two user groups, there were only 29 use errors observed out of 1,216 opportunities for error, despite minimal training. Errors that did occur were minor and attributed to an initial lack of familiarity with the device; none were safety-related.

These results from human factors testing with patients and healthcare professionals demonstrate that SC+ is easy to use—even with minimal training and a significant learning decay period—while offering a high level of use safety.

John E. Milad, Chief Executive Officer of Quanta, said: "*Despite the benefits that home haemodialysis offers, uptake rates are still low and the fear associated with self-managing treatments at home can be a significant barrier. SC+ is a user-friendly, patient-centred personal haemodialysis system, and the findings in this study support our claims that it can address systemic and patient barriers, allowing for wider self-care and home haemodialysis adoption.*"

The full research paper can be viewed on the Hemodialysis International website: https://onlinelibrary.wiley.com/doi/full/10.1111/hdi.12757

-ENDS-

For more information about Quanta, please contact:

Quanta
John E. Milad, Chief Executive Officer
T: +44 (0)1789 400043
E: enquiries@quantadt.com

Consilium Strategic Communications
Mary-Jane Elliott / Matthew Neal / Lindsey Neville
T: +44 (0)203 709 5708
E: quanta@consilium-comms.com

About SC+

SC+ is a small, simple and powerful haemodialysis system designed to provide greater flexibility around where, when and how patients manage and receive their dialysis therapy. As a CE marked medical device, SC+ has been successfully piloted with the NHS, demonstrating clinical efficacy and performance compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The small form factor and simple-to-use design are intended to enable a broader range of users—including patients themselves—to manage dialysis therapy delivery across a wide range of settings—from the clinic to the home.

About Quanta

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta's lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK, and was founded in 2008 as a spin out from IMI plc. The company has attracted funding from a group of leading investors, including: Wellington Partners, Seroba Life Sciences, b-to-v Partners, Stage Capital, ALIAD, CITA, Seventure Partners and Kuwait Life Sciences Company.

For more information, please visit: www.quantadt.com.

SC+ is not yet FDA cleared and not yet available for sale in the USA.